Institutional investors in China are flooding capital into brain-computer interface technologies as breakthroughs move rapidly from academic laboratories into clinical trials and consumer markets, backed by landmark regulatory filings and national policy support.
The surge in financial backing follows a series of technical and regulatory milestones. On Nov. 5, a lower-limb stroke rehabilitation project developed by Tianjin University’s Haihe Laboratory of Brain-Computer Interaction and Human-Machine Integration became the first non-invasive brain-computer interface (BCI) project to complete official clinical trial filing under China’s National Health Commission Decree No. 818.
The clinical trial, conducted in partnership with Tianjin Huanhu Hospital, Huishei Intelligent Technology, and Beijing Pintech Medical Equipment, evaluates a spinal cord stimulation system combined with a non-invasive brain-controlled hybrid exoskeleton. Regulators and industry experts say the filing marks the formal entry of non-invasive neural technology into standardized clinical evaluation in China.
The regulatory green light has triggered renewed movement in mainland financial markets. Although Chinese BCI concept stocks declined by an average of 21.49 percent year-to-date through early November, trading volume has rebounded sharply. Data from Securities Times indicates that 15 BCI-related equities saw their average daily trading volumes surge by more than 10 percent month-over-month in November.
Among those active equities, institutional investors registered net purchases exceeding 10 million yuan ($1.4 million) each across six key stocks: game developer Tom Cat, entertainment giant 37 Interactive Entertainment, sensor maker Hanwei Electronics, artificial intelligence firm Rock Mobile Technology, acoustic device manufacturer Jiahe Intelligent, and medical device maker Lepu Medical.
Commercial interest is accelerating as startup teams attempt to resolve persistent technical bottlenecks in non-invasive BCI hardware. In Changsha, Hunan province, Gen Z led startup Mind Scale Technology Co., Ltd. raised more than 10 million yuan ($1.4 million) in seed funding within six months of launching from a three-desk incubator space at the National University of Defense Technology.
Led by Chief Executive Officer Dr. Huang Junwen, a former Munich University of Technology scholar, and Chief Technology Officer Zhang Yifan, a doctoral researcher under Chinese Academy of Sciences academician Hu Dewen, the startup is developing a universal brain-computer fusion operating system designated BCI-OS.
The platform functions as a standardized software mold designed to translate weak, noisy brainwave signals picked up through the skull and skin into actionable digital commands. Rather than relying solely on gathering larger volumes of raw brainwave data, Mind Scale built a knowledge graph analyzing 1,600 academic papers, 400 specific interaction paradigms, and 12 cognitive processes. The system automates paradigm generation and verification using artificial intelligence engines.
Mind Scale’s founders turned down offers from major tech conglomerates and academic posts to build their system, setting an unconventional benchmark for their technology: training a non-invasive BCI array to direct a robotic hand to peel a spicy crayfish in real time.
While working toward complex robotics control, the firm has already commercialized its core modules. Its first commercial order came from a maternal health enterprise to build wearable BCI modules for emotional tracking, postpartum depression screening, and mindfulness training. The company is simultaneously running joint research initiatives with hospitals for medical device certification and collaborating with industrial AI firms to monitor cognitive fatigue in high-risk occupations.
The convergence of capital and clinical research reflects broader policy momentum. In March 2026, China’s central government formally included brain-computer interfaces alongside quantum technology and embodied artificial intelligence as strategic industries of the future in its annual Government Work Report. That followed multi-department guidelines issued by the National Health Commission to govern medical AI and neural infrastructure deployment.
Global medical equipment makers are expanding their clinical footprints in response. At the 9th China International Import Expo in Shanghai, Medtronic showcased its closed-loop neural ecosystem built around its next-generation Percept deep brain stimulation series. Using real-time sensing technology, the device detects disease-related brain signals, analyzes fluctuations, and dynamically adjusts therapeutic stimulation, moving clinical neurology from fixed-rate stimulation to individual adaptive therapy.
Market analysts note that the transition from static lab demonstrations to automated software frameworks, clinical trials, and institutional stock allocations indicates China’s neural technology sector is bridging the gap between experimental research and broad commercial scale.
